Volume 26, Issue 115 (5-2018)                   J Adv Med Biomed Res 2018, 26(115): 129-139 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yaghoubi A, Roshanaei G, Rafiee M, Tapak L, Sedigipashaki A. Factors Related to the Survival of Patients with Breast Cancer in Hamedan Based on the Competitive Risks. J Adv Med Biomed Res 2018; 26 (115) :129-139
URL: http://journal.zums.ac.ir/article-1-5056-en.html
Factors Related to the Survival of Patients with Breast Cancer in Hamedan Based on the Competitive Risks
Azadeh Yaghoubi1 , Ghodratollah Roshanaei2 , Mohammad Rafiee *3 , Lili Tapak2 , Abdolazim Sedigipashaki4
1- Dept.of Bio Statistics, Arak University of Medical Sciences, Arak, Iran
2- Dept.of Bio Statistics, Hamedan University of Medical Sciences, Hamedan, Iran
3- Dept.of Bio Statistics, Arak University of Medical Sciences, Arak, Iran , rafeie@yahoo.com
4- Mahdieh Radiotherapy Center, Hamedan University of Medical Sciences, Hamedan, Iran
Abstract:   (154272 Views)

Background and Objective: Breast cancer is one of the most common cancers in women worldwide. This study was conducted to analyze the factors related to survival of patients with breast cancer using two models of Cox proportional specific-cause and sub-distribution models (direct modeling of cumulative incidence). These patients were at the competitive risk of death from breast cancer and also death due to other causes that the occurrence of any of these events prevented another from happening.
Materials and Methods: This historical cohort study comprised 573 breast cancer patients who had referred to the Mahdieh medical center of Hamedan during 2004 to 2011 and were followed until 2015. To determine the risk factors among the competitive risks, the Cox specific-cause and cumulative incidence models were fitted. The data were analyzed using the SPSS and R softwares.
Results: The findings showed that among the causes of breast cancer death in the cumulative incidence model, only the tumor size had a significant effect (p = 0.0054) and for death due to other causes in the Cox model, the tumor size was also significant (P = 0.033).  However, the other variables in two models had no significant effect on death.
Conclusion: Considering the significance of the tumor size in the survival of breast cancer patients, the Cox model takes no account of the other risk information with censorship, the cumulative incidence function is recommended to be used in modeling the risk factors in breast cancer.

Keywords: Cumulative survival rate, Competitive risks, Cox model, Breast cancer, Survival
Full-Text [PDF 2787 kb]   (156853 Downloads)    
Type of Study: Clinical Trials |
Received: 2018/02/5 | Accepted: 2018/02/5 | Published: 2018/02/5
References
1. Nottage MK, Kopciuk KA, Tzontcheva A, Andrulis IL, Bull SB, Blackstein ME. Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on diseasespecific survival of women with node-negative breast cancer. a prospective cohort study. Breast Cancer Res. 2006; 8: 44. [DOI:10.1186/bcr1531] [PMID] [PMCID]
2. Center of management of noncontiguous diseases. IRAN Ministry of Health and Medical Education. Iran. Cancer Registry Report. 2015; 21: 1-10.
3. Azizi F, Hatami H, Janghorban M. Epidemiology and control of common diseases. Tehran: Publication of Eshtiagh. 2000; 7-10.
4. Jason P, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc .1999; 94: 496-509. [DOI:10.1080/01621459.1999.10474144]
5. Klein JP, Bajorunaite R. Inference for competing risks, In: Advances in survival analysis, Handbook of statistics. Amsterdam: Elsevier. 2004; 291-311. [DOI:10.1016/S0169-7161(03)23016-9]
6. Tai BC, Wee J, Machin D. Analysis and design of randomised clinical trials involving competing risks endpoints. Trials. 2011; 12: 127. [DOI:10.1186/1745-6215-12-127] [PMID] [PMCID]
7. Zhang M, Zhang XU, Scheike T. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol. 2008; 1: 391-400. [DOI:10.1586/17512433.1.3.391] [PMID] [PMCID]
8. Jafarabadi M, Mohammadi M, Hajizade E, Fatemi R. An evulation of 5-year survival of metastatic colon and rectal cancer patients using cumulative incidence models. Koomesh. 2013. 2: 207-214.
9. Nazemi pur M, Mahmoodi M, Zeraati H, Rahimi Furushani A. Analyze the survival of patients with gastric cancer after surgery, based on a flexible model for competing risks. School of Public Health and Institute of Health Research. 2012; 27-38.
10. McArdle CS, McMillan DC, Greenlaw N, Morrison DS. Adjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival. BMC Cancer. 2010; 10: 398 [DOI:10.1186/1471-2407-10-398] [PMID] [PMCID]
11. Grambauer N, Schumacher M, Beyersmann J. Proportional subdistribution hazards modeling offers a summary analysis, even if misspecified. Stat Med. 2010; 29: 875-84. [DOI:10.1002/sim.3786] [PMID]
12. Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ. Predictors of competing mortality in early breast cancer. Cancer. 2010; 116: 5365-73. [DOI:10.1002/cncr.25370] [PMID]
13. Lim HJ, Zhang X, Dyck R, Osgood N. Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes. BMC Med Res Methodol. 2010; 10: 97. [DOI:10.1186/1471-2288-10-97] [PMID] [PMCID]
14. Torner A.Proportional hazards and additive regression analysis of survival for severe breast cancer.Stockholm: Mathematical Statistic Stockholm University; 2004.
15. Baldi I, Ciccone G, Ponti A, Rosso S, Zanetti R, Gregori D. An application of the cox-aalen model for breast cancer survival. Austrian J statistics. 2006; 35: 77-88. [DOI:10.17713/ajs.v35i1.350]
16. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival analysis. Br J Cancer. 2004; 91: 1229-35. [DOI:10.1038/sj.bjc.6602102] [PMID] [PMCID]
17. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer. differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004; 6: 8-17. [DOI:10.1186/bcr658] [PMID] [PMCID]
18. Olsen J, Christensen K, Murray J, Ekbom A. An introduction to epidemiology for health professionals. New York: Springer, 2010; 5: 14-16.
19. Putter H, Andersen P, Geskus R. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012; 41: 861-70. [DOI:10.1093/ije/dyr213] [PMID] [PMCID]
20. Klein JP. Modelling competing risks in cancer studies. Stat Med. 2006; 25: 1015-34. [DOI:10.1002/sim.2246] [PMID]
21. Latouche A, Boisson V, Chevret S, Porcher R. Misspecified regression model for the subdistribution hazard of a competing risk. Stat Med. 2007; 26: 965-74. [DOI:10.1002/sim.2600] [PMID]
22. Wolbers M, Koller M, Witteman J. Concordance for prognostic models with competing risks. University of Copenhagen, Department of Biostatistics; 2013. [DOI:10.1093/biostatistics/kxt059] [PMID] [PMCID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb